SELLAS Life Sciences Group (NASDAQ:SLS) Hits New 12-Month High – Time to Buy?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) hit a new 52-week high on Tuesday . The stock traded as high as $5.42 and last traded at $5.36, with a volume of 4998925 shares. The stock had previously closed at $5.05.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $7.00.

SELLAS Life Sciences Group Trading Up 8.7%

The firm has a market cap of $782.01 million, a P/E ratio of -19.61 and a beta of 2.27. The business has a 50-day moving average price of $3.96 and a 200-day moving average price of $2.56.

Hedge Funds Weigh In On SELLAS Life Sciences Group

Hedge funds and other institutional investors have recently modified their holdings of the business. Axxcess Wealth Management LLC purchased a new stake in SELLAS Life Sciences Group during the third quarter worth $26,000. Larson Financial Group LLC bought a new position in shares of SELLAS Life Sciences Group in the 4th quarter worth $26,000. BNP Paribas Financial Markets lifted its stake in shares of SELLAS Life Sciences Group by 89.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock worth $32,000 after purchasing an additional 9,299 shares during the last quarter. Concurrent Investment Advisors LLC bought a new stake in SELLAS Life Sciences Group during the fourth quarter valued at about $38,000. Finally, Beacon Pointe Advisors LLC purchased a new position in SELLAS Life Sciences Group in the fourth quarter valued at about $38,000. 17.38% of the stock is currently owned by institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.